Axsome Therapeutics Reports Strong Preliminary Q4 and Full Year 2025 Revenue Growth
Summary
Axsome Therapeutics reported preliminary Q4 and full year 2025 net product revenues, showing substantial annual growth of 65% and 66% respectively, driven by strong sales of AUVELITY, SUNOSI, and SYMBRAVO.
Key Events
-
Preliminary Q4 2025 Revenue
Total net product revenue reached $196.0 million, marking a 65% increase year-over-year.
-
Preliminary Full Year 2025 Revenue
Total net product revenue hit $638.5 million, representing a 66% annual growth.
-
AUVELITY Sales Performance
AUVELITY contributed significantly with $155.1 million in Q4 and $507.1 million for the full year 2025.
-
SUNOSI and SYMBRAVO Contributions
SUNOSI generated $36.7 million in Q4 and $124.8 million for the full year, while SYMBRAVO, launched in June 2025, added $4.1 million in Q4 and $6.6 million for the full year.
Analysis
Axsome Therapeutics announced robust preliminary net product revenues for Q4 and full year 2025, driven by strong performance across its key products, particularly AUVELITY. The significant annual growth rates of 65% and 66% for the quarter and full year, respectively, indicate strong commercial execution and market acceptance of its CNS treatments. This positive revenue trajectory is a key indicator of the company's operational success and potential for continued growth in the biopharmaceutical sector.
At the time of this filing, AXSM was trading at $171.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $79.19 to $184.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.